Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005
by East Valley Hematology and Oncology Medical Group.
Recruitment status was Recruiting
Study NCT00131313 Information provided by East Valley Hematology and Oncology Medical Group
First Received on August 16, 2005. Last Updated on August 17, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Lymphocytic Leukemia
Additional conditions recognized in this trial
Leukemia, Lymphocytic, Chronic, B-Cell
More general conditions related to this trial
Immune System Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
Nipent, Cytoxan, Rituxan
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Adenosine Deaminase Inhibitors
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sponsors listed in this trial
East Valley Hematology and Oncology Medical Group
Mena, Raul, M.D.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers